AR082566A1 - Formulaciones liquidas de st-246 y metodos relacionados, proceso - Google Patents

Formulaciones liquidas de st-246 y metodos relacionados, proceso

Info

Publication number
AR082566A1
AR082566A1 ARP110102829A ARP110102829A AR082566A1 AR 082566 A1 AR082566 A1 AR 082566A1 AR P110102829 A ARP110102829 A AR P110102829A AR P110102829 A ARP110102829 A AR P110102829A AR 082566 A1 AR082566 A1 AR 082566A1
Authority
AR
Argentina
Prior art keywords
polymorph form
cyclodextrin
related methods
liquid formulations
liquid
Prior art date
Application number
ARP110102829A
Other languages
English (en)
Inventor
Dennis E Hruby
Peter N K Samuel
William C Weimers
Tove C Bolken
Shanthakumar R Tyavanagimatt
Melialani A C L Stone
Gopi Krishna Kasi
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of AR082566A1 publication Critical patent/AR082566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24071—Demonstrated in vivo effect

Abstract

Reivindicación 1: Una formulación farmacéutica líquida que comprende una cantidad terapéuticamente eficaz de ST-246 y ciclodextrina, y que además comprende uno o más ingredientes farmacéuticamente aceptables.Reivindicación 3: La formulación farmacéutica líquida de la reivindicación 1, en donde dicha ciclodextrina es hidroxipropiI-b-ciclodextrina. Reivindicación 22: Un proceso para hacer una formulación líquida de acuerdo a la reivindicación 1 que comprende los pasos de: a) mezclar ST-246 con ciclodextrina en un vehículo líquido farmacéuticamente aceptable; y b) opcionalmente filtrar la mezcla de paso a). Reivindicación 23: El proceso de la reivindicación 22, en donde dicha ST-246 se elige del grupo que consiste en ST-246 polimorfa Forma I, ST-246 polimorfa Forma II, ST-246 polimorfa Forma III, ST-246 polimorfa Forma IV, ST-246 polimorfa Forma V y ST-246 polimorfa Forma VI.
ARP110102829A 2010-08-05 2011-08-04 Formulaciones liquidas de st-246 y metodos relacionados, proceso AR082566A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37097110P 2010-08-05 2010-08-05
US201161450359P 2011-03-08 2011-03-08

Publications (1)

Publication Number Publication Date
AR082566A1 true AR082566A1 (es) 2012-12-19

Family

ID=45559790

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102829A AR082566A1 (es) 2010-08-05 2011-08-04 Formulaciones liquidas de st-246 y metodos relacionados, proceso

Country Status (15)

Country Link
US (5) US9233097B2 (es)
EP (1) EP2600715B1 (es)
JP (1) JP5898196B2 (es)
KR (1) KR101868117B1 (es)
CN (2) CN106074370A (es)
AR (1) AR082566A1 (es)
AU (1) AU2011285871B8 (es)
BR (1) BR112013002646B1 (es)
CA (1) CA2807528C (es)
DK (1) DK2600715T3 (es)
IL (1) IL224430B (es)
MX (2) MX368106B (es)
SG (3) SG187243A1 (es)
WO (1) WO2012018810A1 (es)
ZA (1) ZA201300930B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104414983B (zh) * 2013-08-28 2018-09-04 山东新时代药业有限公司 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺
WO2015077143A1 (en) 2013-11-19 2015-05-28 Siga Technologies, Inc. Rehydration of micronized tecovirimat monohydrate
US10413517B2 (en) * 2014-06-12 2019-09-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
WO2016162673A1 (en) 2015-04-10 2016-10-13 Bae Systems Plc Long range sensor apparatus and method of providing a long range sensor apparatus
CN107625967B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN107638571B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN106407676A (zh) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 一种基于蒙特卡罗模拟的抗菌药物药效计算方法
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US20230082992A1 (en) * 2021-09-11 2023-03-16 Viron Therapeutics LLC Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
US11903962B1 (en) 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080080A1 (en) 2002-03-21 2003-10-02 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
ES2632313T3 (es) * 2003-06-20 2017-09-12 Siga Technologies Inc. Compuestos, composiciones y métodos para el tratamiento y la prevención de infecciones por ortopoxvirus y enfermedades asociadas
EP1831210A1 (en) * 2004-12-23 2007-09-12 Pfizer Limited 8-aza-bicyclo[3.2.1]octane derivatives with an activity on chemokine ccr5 receptors
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
DK2581078T3 (en) * 2005-10-26 2015-03-02 Cydex Pharmaceuticals Inc Sulfoalkylætercyclodekstrinsammensætninger and processes for the preparation thereof
CA2669705A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
CN101702904A (zh) 2007-04-23 2010-05-05 西佳技术公司 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
CA2732437C (en) * 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use

Also Published As

Publication number Publication date
US9907859B2 (en) 2018-03-06
US10124071B2 (en) 2018-11-13
US20160082128A1 (en) 2016-03-24
EP2600715A1 (en) 2013-06-12
WO2012018810A1 (en) 2012-02-09
US20200138974A1 (en) 2020-05-07
WO2012018810A9 (en) 2012-04-05
KR20130135836A (ko) 2013-12-11
IL224430B (en) 2019-09-26
CN103281898A (zh) 2013-09-04
MX368106B (es) 2019-09-19
EP2600715B1 (en) 2019-12-11
US10864282B2 (en) 2020-12-15
AU2011285871A1 (en) 2013-02-21
JP2013532729A (ja) 2013-08-19
US20180185514A1 (en) 2018-07-05
SG187243A1 (en) 2013-02-28
CA2807528C (en) 2018-09-25
ZA201300930B (en) 2015-11-25
MX347795B (es) 2017-05-12
AU2011285871B2 (en) 2015-04-23
CN106074370A (zh) 2016-11-09
JP5898196B2 (ja) 2016-04-13
EP2600715A4 (en) 2016-04-20
AU2011285871B8 (en) 2015-05-14
SG10202105262QA (en) 2021-06-29
US20190038767A1 (en) 2019-02-07
SG10201506031UA (en) 2015-09-29
US10576165B2 (en) 2020-03-03
KR101868117B1 (ko) 2018-06-18
US9233097B2 (en) 2016-01-12
BR112013002646A2 (es) 2013-02-04
MX2013001389A (es) 2013-06-07
AU2011285871A8 (en) 2015-05-14
CA2807528A1 (en) 2012-02-09
US20140011854A1 (en) 2014-01-09
BR112013002646B1 (pt) 2022-01-04
DK2600715T3 (da) 2020-03-16

Similar Documents

Publication Publication Date Title
AR082566A1 (es) Formulaciones liquidas de st-246 y metodos relacionados, proceso
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
PE20130230A1 (es) Derivados de carboxamidas n-azabiciclicas y su preparacion
EA201391758A1 (ru) Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
EA201001555A1 (ru) Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
NZ709958A (en) Enhanced stability of novel liquid compositions
EA201391313A1 (ru) C4-монометилтритерпеноидные производные и способы их применения
CR20140113A (es) Imidazopiridazinas sustituidas con amino
CL2012000261A1 (es) Composición farmacéutica líquida de ácido 4- {[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico en una mezcla de disolventes con al menos 15% de propilenglicol, 15% de peg400 y menos de 50% de agua; y su uso para la preparación de un medicamento para el tratamiento de cáncer.
MD3310345T2 (ro) Comprimată orodispersabilă ce conține estetrol
MX2015008427A (es) Proceso de granulacion en seco para producir composiciones de comprimidos de metformina y sus composiciones.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
MD3310346T2 (ro) Comprimată orodispersabilă ce conține estetrol
CR20140037A (es) Antagonistas trpm8 y su uso en tratamientos
AR089990A1 (es) Dispositivo con nucleo y recubrimiento para la liberacion de farmacos
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
WO2013006308A3 (en) Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
UY34273A (es) Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
NI201100014A (es) Composiciones farmacéuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides, y su uso.
WO2011063774A3 (en) Pectin complexes of steroids and pharmaceutical compositions based thereon
MX346497B (es) Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos.

Legal Events

Date Code Title Description
FC Refusal